A STUDY OF THE EFFECT OF METHYLCOBALAMIN AND ADHD

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 这项试点研究的具体目标有三个： 1. 确定甲钴胺与安慰剂相比对脑电图（EEG变化）的急性影响。 2. 确定甲钴胺与安慰剂相比对神经认知能力的急性影响。 3. 如果上述目标得以实现，它们将导致更大、更明确的试验。更大规模的试验不仅将包括更多数量的受试者，而且将被设计为评估单次给药后注意力改善的持续时间，以及在较长时间内（例如几周）是否观察到认知改善。显然需要有效的ADHD治疗，这种治疗更安全，减少药物滥用的可能性，甲基钴胺素可能是这种治疗的一个例子。有效性的初步证据将增加药品或营养品制造商或政府资助机构支持建立有效性和安全性所需的全面试验的可能性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: The specific aims of this pilot study are threefold: 1. To determine the acute effects of Methylcobalamin, as compared to placebo, on electroencephalogram (EEG changes. 2. To determine the acute effects of Methylcobalamin, as compared to placebo, on neurocognitive performance. 3. If the above goals were met, they would lead to a larger, more definitive trial. The larger trial would not only include a larger number of subjects, but would be designed to evaluate the duration of improvement in attention from a single dose as well whether improvements in cognition are observed over an extended period of time (e.g. several weeks). There exists a clear need for effective ADHD treatments that are safer and carry a reduced potential for drug abuse, and Methylcobalamin may prove to be an example of such a treatment. Preliminary evidence of effectiveness will increase the likelihood that Pharmaceutical or Nutriceutical manufacturers or government funding agencies will support full trials that are necessary to establish efficacy and safety.